SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rentokil Initial plc - RTO


Werte in diesem Artikel
Aktien

5.22 EUR -0.05 EUR -0.99 %

NEW YORK, Nov. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Rentokil Initial plc ("Rentokil" or the "Company") (NYSE: RTO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

The investigation concerns whether Rentokil and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On September 11, 2024, Rentokil disclosed that it expected full-year adjusted pretax profit of approximately £700 million, compared to £766 million in the previous year, citing weaker than expected sales in North America, the Company's largest market. Rentokil also stated that it would cut an undisclosed number of jobs in its U.S. workforce to address cost overruns. 

On this news, Rentokil's American depositary receipt ("ADR") price fell $6.64 per ADR, or 21.04%, to close at $24.95 per ADR on September 11, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-rentokil-initial-plc---rto-302294466.html

SOURCE Pomerantz LLP

Aktuelle Rentokil Initial Aktie News

Werbung

Rentokil Initial Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Rentokil Initial nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
DatumRatingAnalyst
18.03.13 Rentokil Initial verkaufen Exane-BNP Paribas SA
27.02.13 Rentokil Initial verkaufen Exane-BNP Paribas SA
28.11.12 Rentokil Initial underperform Exane-BNP Paribas SA
09.05.12 Rentokil Initial overweight Morgan Stanley
08.11.11 Rentokil Initial overweight Morgan Stanley